p53 Immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance

The expression of p53 protein was immunohistochemically studied in formalin-fixed paraffin-embedded biopsy specimens of 203 colorectal carcinomas by use of a monoclonal antibody specific for the p53 protein. PAb1801. p53 protein expression with its reactivity localised in nuclei was found in 121 (59...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1993-08, Vol.68 (2), p.399-402
Main Authors: YAMAGUCHI, A, NAKAGAWARA, G, KUROSAKA, Y, NISHIMURA, G, YONEMURA, Y, MIYAZAKI, I
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Biological and medical sciences
Biopsy
Colonic Neoplasms - mortality
Colonic Neoplasms - pathology
Colonic Neoplasms - surgery
Colonoscopy
Follow-Up Studies
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver Neoplasms - secondary
Lymphatic Metastasis
Medical sciences
Neoplasm Invasiveness
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Rectal Neoplasms - mortality
Rectal Neoplasms - pathology
Rectal Neoplasms - surgery
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Analysis
Time Factors
Tumor Suppressor Protein p53 - analysis
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of p53 protein was immunohistochemically studied in formalin-fixed paraffin-embedded biopsy specimens of 203 colorectal carcinomas by use of a monoclonal antibody specific for the p53 protein. PAb1801. p53 protein expression with its reactivity localised in nuclei was found in 121 (59.6%) of the cancers. There was no correlation of p53 immunoreactivity with histological classification, wall invasion, lymphatic invasion, venous invasion, lymph node metastases, or peritoneal metastases. p53-positive cancers were more frequently associated with liver metastasis than p53-negative ones. Patients with p53-positive tumours had significantly poorer prognoses than those with p53-negative tumours. The 5 year survival rate was 58.1% for patients with p53-positive tumours, and 76.3% for those with p53-negative tumours. In Dukes' stage C tumours, an especially good correlation was found between p53 immunoreactivity and prognosis. In addition, patients with p53-positive tumours had higher recurrence rates. The results indicate that p53 immunoreactivity may be a useful prognostic marker of colorectal cancers.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1993.348